{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:41:39Z","timestamp":1794627699053,"version":"4.9.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.atherosclerosis.2025.120627","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T16:14:49Z","timestamp":1766420089000},"page":"120627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Evinacumab in patients aged 5\u201317 years with homozygous familial hypercholesterolemia"],"prefix":"10.1016","volume":"413","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-0633","authenticated-orcid":false,"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot A.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carissa","family":"Baker-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Greber-Platzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"McCrindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpana","family":"Waldron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Qiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Wiegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2025.120627_bib1","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029175","article-title":"Contemporary homozygous familial hypercholesterolemia in the United States: insights from the CASCADE FH registry","volume":"12","author":"Cuchel","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib3","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"issue":"Suppl 5","key":"10.1016\/j.atherosclerosis.2025.120627_bib4","first-page":"S213","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib5","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.574474","article-title":"Genetics of familial hypercholesterolemia: new insights","volume":"11","author":"Vrablik","year":"2020","journal-title":"Front Genet"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.atherosclerosissup.2014.07.004","article-title":"Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement","volume":"15","author":"Bruckert","year":"2014","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib10","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0140-6736(93)90815-X","article-title":"Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia","volume":"341","author":"Moorjani","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib11","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia","volume":"20","author":"Watts","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2016.10.017","article-title":"HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom","volume":"255","author":"France","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100060","article-title":"Existing and emerging therapies for the treatment of familial hypercholesterolemia","volume":"62","author":"Rosenson","year":"2021","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MOL.0000000000000686","article-title":"Evidence for improved survival with treatment of homozygous familial hypercholesterolemia","volume":"31","author":"B\u00e9langer","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib17","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib18","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1538\/expanim.55.27","article-title":"Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity","volume":"55","author":"Fujimoto","year":"2006","journal-title":"Exp Anim"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","article-title":"Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase","volume":"27","author":"Shimamura","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib26","author":"Ultragenyx Japan"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib28","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy","volume":"45","author":"Gaudet","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100648","article-title":"The long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia","volume":"2","author":"Raal","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib31","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.atherosclerosis.2020.10.119","article-title":"Evaluating the effect of lipid-apheresis on evinacumab and angiopoietin-like 3 (ANGPTL3) levels","volume":"315","author":"Moriarty","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(24)00233-X","article-title":"Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study","volume":"12","author":"Masana","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/01.ATV.9.2.211","article-title":"Homozygous familial hypercholesterolemia among French Canadians in Qu\u00e9bec Province","volume":"9","author":"Moorjani","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.281.6241.633","article-title":"A host of hypercholesterolaemic homozygotes in South Africa","volume":"281","author":"Seftel","year":"1980","journal-title":"Br Med J"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0021-9258(19)75941-9","article-title":"The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum","volume":"262","author":"Lehrman","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s004390050243","article-title":"Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations","volume":"98","author":"Steyn","year":"1996","journal-title":"Hum Genet"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib37","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib38","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120627_bib39","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/eurjpc\/zwad203","article-title":"Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia","volume":"30","author":"Gu","year":"2023","journal-title":"Eur J Prev Cardiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025015254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025015254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:13:45Z","timestamp":1773954825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025015254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":33,"alternative-id":["S0021915025015254"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120627","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evinacumab in patients aged 5\u201317 years with homozygous familial hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120627"}}